Comparison of Lucentic (Ranibizumab) and Ozurdex (Dexamethasone) for the treatment of patients with visual impairment due to macular edema following branch retinal vein occlusion

Update Il y a 4 ans
Reference: EUCTR2011-001019-30

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

The primary objective is to show that ranibizumab (administered in an individualized treatment regimen) has superior efficacy and safety compared to Dexamethasone implant (Ozurdex®) over a 6 months period


Inclusion criteria

  • Visual Impairment due to macular oedema following branch retinal vein occlusion (BRVO)